Editor's Correspondence |

The Big Ones That Got Away: Omega-3 Meta-analysis Flawed by Excluding the Biggest Fish Oil Trials

James J. DiNicolantonio, PharmD; James H. O’Keefe, MD; Carl J. Lavie, MD
Arch Intern Med. 2012;172(18):1427-1428. doi:10.1001/archinternmed.2012.3755.
Text Size: A A A
Published online


Kwak et al1(p686) state that “Our meta-analysis showed insufficient evidence of a secondary preventive effect of omega-3 fatty acid supplements against overall cardiovascular events among patients with a history of cardiovascular disease.” We respectfully disagree with this conclusion. This meta-analysis mainly included trials comprising only 50 to 550 patients with just 2 years or less of follow-up (the point at which the survival curves started to diverge in the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico [GISSI] Heart Failure study2) in 10 of the 14 trials. In addition, 5 of the 14 trials were, in fact, not truly placebo controlled but used olive oil as a comparator. Kromhout et al3 used omega-3 fatty acids in margarine spread over multiple pieces of toast per day, which could nullify any beneficial effects of fish oil. Most included trials were not powered to detect a difference in cardiovascular outcomes (OMEGA4 and the SU.FOL.OM3 [Supplémentation en Folates et Omega-3]5 studies had approximately 20% power to detect a 25% benefit of omega-3 and the Alpha Omega study3 [used just 380 mg/d of eicosapentanoic acid + docosahexaenoic acid] had approximately half the statistical power as the GISSI-Prevenzione study6). Thus, a “lack of inclusion of sufficient trial data” should not be interpreted as “insufficient evidence at preventing cardiovascular events.”

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview





October 8, 2012
Sang Mi Kwak, MD; Seung-Kwon Myung, MD
Arch Intern Med. 2012;172(18):1427-1428. doi:10.1001/archinternmed.2012.4300.
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
PubMed Articles